Helen Byakwaga

Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium.

Cancer remains a leading cause of morbidity and mortality in people with HIV, and the importance of cancer screening increases as this population ages. In 2017, 2020, and 2023, cross-sectional surveys were conducted at HIV care sites across 5 continents within the International e...

Hepatitis B and C Prevention, Screening and Diagnostic Services at HIV Treatment Sites: International epidemiology Databases to Evaluate AIDS.

Background Prevention, screening and diagnostic services for hepatitis B virus (HBV) and hepatitis C virus (HCV) can prevent morbidity and mortality in people receiving HIV care. However, there is limited information about the availability of HBV and HCV services at HIV clinics g...

Continued high mortality following diagnosis of HIV-associated Kaposi sarcoma in East Africa in the “Treat All” antiretroviral therapy era ― 2021-2024

Abstract Background Stage at time of diagnosis and survival after diagnosis are critical parameters regarding control of any cancer in any geographical setting. In earlier research focusing on the initial years of the “Treat All” era (2016-2019), we found that HIV-associated Kapo...